➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Dow
Colorcon
Baxter
Boehringer Ingelheim

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for LY2157299

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug LY2157299?

LY2157299 is an investigational drug.

There have been 23 clinical trials for LY2157299. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Pancreatic Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, University of Campania "Luigi Vanvitelli", and University of California, Los Angeles.

There are seven US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for LY2157299
TitleSponsorPhase
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAgendiaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAzienda Ospedaliera Niguarda Cà GrandaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerCatalan Institute of HealthPhase 1/Phase 2

See all LY2157299 clinical trials

Clinical Trial Summary for LY2157299

Top disease conditions for LY2157299
Top clinical trial sponsors for LY2157299

See all LY2157299 clinical trials

US Patents for LY2157299

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY2157299   Start Trial Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)   Start Trial
LY2157299   Start Trial Benzotriazole-derived .alpha. and .beta.-unsaturated amide compound used as TGF-.beta. RI inhibitor Genfleet Therapeutics (Shanghai) Inc. (Shanghai, CN) Medshine Discovery Inc. (Nanjing, CN)   Start Trial
LY2157299   Start Trial Quinolinyl-pyrrolopyrazoles Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2157299   Start Trial Quinolinyl-pyrrolopyrazoles Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2157299   Start Trial TGF-.beta. inhibitors Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2157299   Start Trial Compositions and methods for treating and preventing neointimal stenosis Yale University (New Haven, CT)   Start Trial
LY2157299   Start Trial Methods for stimulating hematopoietic recovery by inhibiting TGF.beta. signaling Cornell University (Ithaca, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LY2157299

Drugname Country Document Number Estimated Expiration Related US Patent
LY2157299 World Intellectual Property Organization (WIPO) 2015066053 2033-10-28   Start Trial
LY2157299 Australia 2017284124 2036-06-13   Start Trial
LY2157299 Brazil 112018075736 2036-06-13   Start Trial
LY2157299 Canada 3027425 2036-06-13   Start Trial
LY2157299 China 109415341 2036-06-13   Start Trial
LY2157299 Denmark 3470409 2036-06-13   Start Trial
LY2157299 European Patent Office 3470409 2036-06-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Dow
Colorcon
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.